Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-421 in Multi-Drug Resistant HIV-1
NCT05582694Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semzuvolimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of participants with >=0.5 log10 reduction in HIV-1 plasma viremia and Number of grade 2 or higher adverse events. Planned start Jul 2025; status: withdrawn.
02
Drugs
semzuvolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05582694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582694.